Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.

Journal of cancer research and clinical oncology - 1 Sept 2011

Pan Feng, Tian Jing, Zhang Xuchao, Zhang Ying, Pan Yueyin

Abstract excerpt

PURPOSE: Previous studies have demonstrated that sunitinib has the anti-tumor activity in human non-small cell lung cancer (NSCLC). This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs. METHODS: NSCLC cell lines with EGFR T790M mutation and K-ras mutation were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Drug Synergism

Share to Indoles

Share to Pyrroles

Share to Sunitinib

Share to Taxoids

Source

Identifiers

PMID: 21796416
DOI: 10.1007/s00432-011-1009-x

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.PMID 21796416Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.Semantic proximity Read ↗

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.Semantic proximity Read ↗

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.Semantic proximity Read ↗

Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.Semantic proximity Read ↗

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.Semantic proximity Read ↗

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.Semantic proximity Read ↗

A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.Semantic proximity Read ↗

ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.Semantic proximity Read ↗

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.